SPRC

SciSparc Ltd. [SPRC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

SPRC Stock Summary

Earnings have grown 113.73% per last year.

Does not have any significance market cap ($3.9M)

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

SPRC

Top 10 Correlated Stocks

SPRC

In the News

SPRC Financial details

Company Rating

Market Cap

3.9M

Income

-7.71M

Revenue

4.23M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 Aug 2023

P/E

-7.89

Forward P/E

PEG

-0.35

P/S

8.13

P/B

3.17

P/C

P/FCF

-0.86

Quick Ratio

0.9

Current Ratio

1.09

Debt / Equity

LT Debt / Equity

EPS (TTM)

-48.03

EPS next Y

EPS next Q

EPS this Y

-14.8%

EPS next Y

EPS next 5Y

EPS last 5Y

72.99%

Revenue last 5Y

42.04%

Revenue Q/Q

-54.01%

EPS Q/Q

-68.83%

SMA20

-60.38%

SMA50

-68.45%

SMA100

-65.03%

Inst Own

Inst Trans

ROA

-24%

ROE

-36%

ROC

-1.14%

Gross Margin

76%

Oper. Margin

-548%

Profit Margin

-192%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.58-23.66

52W High

-92.13%

52W Low

+81%

RSI

19.92

Rel Volume

0.12

Avg Volume

1.35M

Volume

156.83K

Perf Week

-18.1%

Perf Month

-68.36%

Perf Quarter

-73.58%

Perf Half Y

-75.77%

Beta

1.399

Volatility

0.19%, 1.4%

Prev Close

-5.73%

Price

1.81

Change

-4.23%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.35M
Market Capitalization 3.9M
Employee 3
CEO Mr. Itschak Shrem
Headquarters Tel Aviv,IL
IPO Date 2021-08-30
Website https://scisparc.com

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.